P147-Bioorgchem-Kanamycin Nucleotidyltransferase-1999.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pharmaceutical Applications Notebook
Pharmaceutical Applications Notebook Antibiotics Table of Contents Index of Analytes .......................................................................................................................................................................3 Introduction to Pharmaceuticals ................................................................................................................................................4 UltiMate 3000 UHPLC+ Systems .............................................................................................................................................5 IC and RFIC Systems ................................................................................................................................................................6 MS Instruments .........................................................................................................................................................................7 Chromeleon 7 Chromatography Data System Software ..........................................................................................................8 Process Analytical Systems and Software ................................................................................................................................9 Automated Sample Preparation ..............................................................................................................................................10 Analysis of Antibiotics ...........................................................................................................................................................11 -
G Genito Urinary System and Sex Hormones
WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. -
A New Mutation in 16S Rrna Ofescherichia Coli
464-466 Nucleic Acids Research, 1995, Vol. 23, No. 3 Q-D/ 1995 Oxford University Press A new mutation in 16S rRNA of Escherichia coli conferring spectinomycin resistance Urban Johanson and Diarmaid Hughes* Department of Molecular Biology, Uppsala University, Biomedical Center, S-751 24 Uppsala, Sweden Received September 24, 1994; Revised and Accepted December 30, 1994 ABSTRACT 1067 1089 A -U We report a novel mutation, Cl 066U in 16S rRNA which was selected for resistance to spectinomycin, an U @- G4C antibiotic which inhibits ribosomal translocation. The U,A,C e- G,U,A minimal inhibitory concentration (MIC) of spectinomy- A cin determined for this mutant (15 pg/ml) is greater U U than with the wild-type plasmid (5 ig/ml) but lower than 1062 1194 with the well known C1192U mutation (>80 pg/ml). The Cl 066U mutation also increases the cells sensitivity to Figure 1. Secondary structure of the upper part of helix 34 of 16S rRNA in fusidic acid, another antibiotic which inhibits transla- Ecoli (24) with the novel C1066U mutation indicated by an open U. In tion at the translocation stage, whereas C1192U is addition, all other known SpcR mutations are shown. The mutations are A1191G,C, Gi 193A in C.reinhardtii chloroplast (25); G1064A (20), A1191C, unchanged relative to the wild type. We discuss why Cl 192U (26) inN.tabacum chloroplast; GI 193A (20) inN.undulata chloroplast the acquisition of resistance to one of these drugs is and C1192U (1), C1192U,G,A (19), G1064U,C,A, G1064U-C1192A, often associated with hypersensitivity to the other. -
Computational Antibiotics Book
Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p. -
(ESVAC) Web-Based Sales and Animal Population
16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1. -
MACROLIDES (Veterinary—Systemic)
MACROLIDES (Veterinary—Systemic) This monograph includes information on the following: Category: Antibacterial (systemic). Azithromycin; Clarithromycin; Erythromycin; Tilmicosin; Tulathromycin; Tylosin. Indications ELUS EL Some commonly used brand names are: For veterinary-labeled Note: The text between and describes uses that are not included ELCAN EL products— in U.S. product labeling. Text between and describes uses Draxxin [Tulathromycin] Pulmotil Premix that are not included in Canadian product labeling. [Tilmicosin Phosphate] The ELUS or ELCAN designation can signify a lack of product Erythro-200 [Erythromycin Tylan 10 [Tylosin availability in the country indicated. See the Dosage Forms Base] Phosphate] section of this monograph to confirm availability. Erythro-Med Tylan 40 [Tylosin [Erythromycin Phosphate] General considerations Phosphate] Macrolides are considered bacteriostatic at therapeutic concentrations Gallimycin [Erythromycin Tylan 50 [Tylosin Base] but they can be slowly bactericidal, especially against Phosphate] streptococcal bacteria; their bactericidal action is described as Gallimycin-50 Tylan 100 [Tylosin time-dependent. The antimicrobial action of some macrolides is [Erythromycin Phosphate] enhanced by a high pH and suppressed by low pH, making them Thiocyanate] less effective in abscesses, necrotic tissue, or acidic urine.{R-119} Gallimycin-100 Tylan 200 [Tylosin Base] Erythromycin is an antibiotic with activity primarily against gram- [Erythromycin Base] positive bacteria, such as Staphylococcus and Streptococcus Gallimycin-100P Tylan Soluble [Tylosin species, including many that are resistant to penicillins by means [Erythromycin Tartrate] of beta-lactamase production. Erythromycin is also active against Thiocyanate] mycoplasma and some gram-negative bacteria, including Gallimycin-200 Tylosin 10 Premix [Tylosin Campylobacter and Pasteurella species.{R-1; 10-12} It has activity [Erythromycin Base] Phosphate] against some anaerobes, but Bacteroides fragilis is usually Gallimycin PFC Tylosin 40 Premix [Tylosin resistant. -
ARK™ Linezolid Assay
1 NAME ARK™ Linezolid Assay 2 INTENDED USE The ARK Linezolid Assay is a homogeneous enzyme immunoassay intended for the quantitative For Export Only – Not For Sale in USA determination of linezolid in human serum on automated clinical chemistry analyzers. The measurements obtained are used in monitoring levels of linezolid to help ensure appropriate therapy. ™ ARK Linezolid Assay 3 SUMMARY AND EXPLANATION OF THE TEST This ARK Diagnostics, Inc. package insert for the ARK Linezolid Assay must be read carefully Linezolid (ZYVOX®, Pfizer, Inc.) [(S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo- prior to use. Package insert instructions must be followed accordingly. Reliability of the assay 5-oxazolidinyl] methyl]-acetamide] is an oxazolidinone derivative with a predominantly results cannot be guaranteed if there are any deviations from the instructions in this package bacteriostatic effect against severe infections caused by methicillin- or vancomycin-resistant insert. The ARK Linezolid Assay test system includes separately provided test kits for the ARK Gram-positive bacteria.1 Linezolid Assay, ARK Linezolid Calibrator and ARK Linezolid Control. ZYVOX is indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia; Community-acquired pneumonia; Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis; Uncomplicated skin and skin structure infections; Vancomycin- CUSTOMER SERVICE resistant Enterococcus faecium infections.2 ARK Diagnostics, Inc. C 4 PRINCIPLES OF THE PROCEDURE 48089 Fremont Blvd Emergo Europe The ARK Linezolid Assay is a homogeneous immunoassay based on competition between drug in the specimen and linezolid labeled with recombinant enzyme glucose-6-phosphate Fremont, CA 94538 USA Prinsessegracht 20 dehydrogenase (rG6PDH) for binding to the antibody reagent. -
THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No
THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 732 , 370 B2 Jagesar ( 45 ) Date of Patent: Aug. 15, 2017 ( 54 ) METHOD FOR THE DETERMINATION OF ( 58 ) Field of Classification Search THE PRESENCE OF AN ANTIBIOTIC IN A None FLUID See application file for complete search history. (71 ) Applicant: DSM IP ASSETS B . V ., Heerlen (NL ) ( 56 ) References Cited ( 72 ) Inventor : Dhiredj Chandre Jagesar , Echt (NL ) U . S . PATENT DOCUMENTS 2007/ 0092929 A1* 4 / 2007 Dekker .. .. .. C12Q 1/ 18 ( 73 ) Assignee : DSM IP ASSETS B . V ., Heerlen (NL ) 435 / 32 ( * ) Notice : Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .C . 154 (b ) by 0 days . EP 0005891 A112 / 1979 EP 0285792 Al 10 / 1988 ( 21) Appl. No .: EP 0611001 AL 8 / 1994 14 /787 , 859 EP 1639122 A1 3 /2006 WO 2005005655 AL 1 / 2005 ( 22 ) PCT Filed : Apr. 30 , 2014 wo 2013057182 AL 4 /2013 ( 86 ) PCT No . : PCT/ EP2014 / 058778 OTHER PUBLICATIONS $ 371 (c ) ( 1 ) , ( 2 ) Date : Oct. 29 , 2015 International Search Report from corresponding PCT/ EP2014 / 058778 , mailed Jul . 23 , 2014 . Gilbertson et al. , “ Modified Microbiological Method for the Screen ( 87 ) PCT Pub . No . : WO2014 / 177597 ing of Antibiotics in Milk ” , 1995 , J. Dairy Sci , vol. 78 , PCT Pub . Date : Nov . 6 , 2014 XP27050235, pp . 1032 - 1038 . (65 ) Prior Publication Data * cited by examiner US 2016 / 0076071 A1 Mar . 17 , 2016 Primary Examiner — Kade Ariani ( 30 ) Foreign Application Priority Data (74 ) Attorney , Agent, or Firm - McBee Moore Woodward & Vanik IP , LLC ; Susan McBee ; Chester May 2 , 2013 (EP ) . -
Fisher Bioreagents Antibiotics and Antimycotics Catalog
Fisher BioReagents® Antibiotics and Antimycotics In many life science laboratories, the in vitro culturing of bacterial, Optimized for cell culture plant, and animal cells is a routine task. High quality antibiotics and antimycotics from Fisher BioReagents can be used to ensure success- ful growth of cells by eliminating unwanted bacterial strains and fungi while maintaining the health and vitality of the desired cells. Advantages • High quality - antibiotics and antimycotics meet rigorous quality control tests, including verifi cation of potency, purity, and solubility using microbiological and chromatographic methods. • Built for selection - excellent choice of antibiotics for selection of antibiotic resistance genes in both bacterial and mammalian cells. • High purity and stability - ultrapure antibiotics ensure successful growth of target cells and reproducible results. • Maximum convenience - antibiotics and antimycotics come in both sterile powder and liquid forms. Applications • Plant cell culture • Mammalian cell culture • Tissue culture • Genetic marker selection Table 1. Antibiotic modes of action Molecular Catalog No. Product Description Mode of Action Susceptible Organisms Form Size Packaging Weight Inhibitor of protein disulfide isomerase. Interferes with BP2950-1 Bacitracin 1422.7 Gram+ Dry 1g Amber glass bottle building blocks of peptidoglycan bacterial cell wall. Inhibitor of bacterial cell wall synthesis. Eliminates BP2951-1 Cefotaxime Sodium Salt 477.5 Gram- Dry 1g Amber glass bottle Agrobacterium species after inoculation. BP2952- Prokaryotes and higher Crimp top on glass Hygromycin B 527.5 Inhibits protein synthesis. Liquid 1mu 1MU eukaryotes bottle Alters membrane permeability and allows potassium ion BP2949-5 Nystatin 926.1 Yeasts and molds Dry 5g Amber glass bottle leakage. BP2953-1 Paromomycin Sulfate 615.6 Inhibits protein synthesis. -
Third ESVAC Report
Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency. -
Sales of Veterinary Antimicrobial Agents in 19 EU/EEA Countries in 2010
Sales of veterinary antimicrobial agents in 19 EU/EEA countries in 2010 Second ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European • We are strongly committed to public and animal Union (EU) body responsible for coordinating the health. existing scientific resources put at its disposal by • We make independent recommendations based on Member States for the evaluation, supervision and scientific evidence, using state-of-the-art knowl- pharmacovigilance of medicinal products. edge and expertise in our field. • We support research and innovation to stimulate The Agency provides the Member States and the the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of • We value the contribution of our partners and the quality, safety and efficacy of medicinal products stakeholders to our work. for human or veterinary use referred to it in accord • We assure continual improvement of our processes ance with the provisions of EU legislation relating to and procedures, in accordance with recognised medicinal products. quality standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleag network, the European Medicines Agency: ues. • We promote the wellbeing, motivation and • provides independent, sciencebased recommen ongoing professional development of every dations on the quality, safety and efficacy of member of the Agency. -
Chlamydia Trachomatis Neisseria Gonorrhoeae
st 21 Expert Committee on Selection and Use of Essential Medicines STI ANTIBIOTICS REVIEW (1) Have all important studies/evidence of which you are aware been included in the application? YES (2) For each of the STIs reviewed in the application, and noting the corresponding updated WHO treatment guidelines, please comment in the table below on the application’s proposal for antibiotics to be included on the EML STI ANTIBIOTICS USED IN WHO AND RECOGNIZED GUIDELINES Chlamydia trachomatis UNCOMPLICATED GENITAL CHLAMYDIA AZITHROMYCIN 1g DOXYCYCLINE 100mg TETRACYCLINE 500mg ERYTHROMYCIN 500mg OFLOXACIN 200mg ANORECTAL CHLAMYDIAL INFECTION DOXYCYCLINE 100mg AZITHROMYCIN 1g GENITAL CHLAMYDIAL INFECTION IN PREGNANT WOMEN AZITHROMYCIN 1g AMOXYCILLIN 500mg ERYTHROMYCIN 500mg LYMPHOGRANULOMA VENEREUM (LGV) DOXYCYCLINE 100mg AZITHROMYCIN 1g OPHTHALMIA NEONATORUM AZITHROMYCIN SUSPENSION ERYTHROMYCIN SUSPENSIONS FOR OCULAR PROPHYLAXIS TETRACYCLINE HYDROCHLORIDE 1% EYE OINTMENT ERYTHROMYCIN 0.5% EYE OINTMENT POVIDONE IODINE 2.5% SOLUTION (water-based) SILVER NITRATE 1% SOLUTION CHLORAMPHENICOL 1% EYE OINTMENT. Neisseria gonorrhoeae GENITAL AND ANORECTAL GONOCOCCAL INFECTIONS CEFTRIAXONE 250 MG IM + AZITHROMYCIN 1g CEFIXIME 400 MG + AZITHROMYCIN 1g SPECTINOMYCIN 2 G IM ou CEFTRIAXONE 250 MG IM ou CEFIXIME 400 MG OROPHARYNGEAL GONOCOCCAL INFECTIONS CEFTRIAXONE 250 MG IM + AZITHROMYCIN 1g CEFIXIME 400 MG + AZITHROMYCIN 1g CEFTRIAXONE 250 MG IM RETREATMENT IN CASE OF FAILURE CEFTRIAXONE 500 mg IM + AZITHROMYCIN 2g CEFIXIME 800 mg + AZITHROMYCIN 2g SPECTINOMYCIN 2 G IM + AZITHROMYCIN 2g GENTAMICIN 240 MG IM + AZITHROMYCIN 2g OPHTALMIA NEONATORUM CEFTRIAXONE 50 MG/KG IM (MAXIMUM 150 MG) KANAMYCIN 25 MG/KG IM (MAXIMUM 75 MG) SPECTINOMYCIN 25 MG/KG IM (MAXIMUM 75 MG) FOR OCULAR PROPHYLAXIS, TETRACYCLINE HYDROCHLORIDE 1% EYE OINTMENT ERYTHROMYCIN 0.5% EYE OINTMENT POVIDONE IODINE 2.5% SOLUTION (water-based) SILVER NITRATE 1% SOLUTION CHLORAMPHENICOL 1% EYE OINTMENT.